US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

• Source: Shutterstock

A potential label for the US consumer health product industry’s January-March period might be the dismissal of a challenge to an iconic analgesic’s label and the easing of a regulatory burden for filing OTC label updates combined with the introduction of a first-ever nonprescription label.

US OTC drug and dietary supplement firms’ reports of their results for the first three months of 2024 begins on...

More from Earnings

More from Business